Clinical trials: Utidelone
Breast Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN)
Simple Surgical Glove Compression to Prevent Chemotherapy-Induced Peripheral Neuropathy
To evaluate the preventive efficacy of a simple surgical glove compression technique in reducing the incidence and severity of Chemotherapy Induced Peripheral Neuropathy among patients receiving chemotherapy.
- Conditions
- Breast Cancer, Chemotherapy Induced Peripheral Neuropathy (CIPN), Neoadjuvant Therapy
- Trial name
- NCT07169864
- Testing
- Simple Surgical Glove Compression Technique
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Jinsong Lu
Solid Tumor
Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors
This trial is an open, two-stage, multi-center, phase II clinical trial to evaluate the efficacy and safety of Utidelone in advanced solid tumors (excluding breast cancer, lung cancer, and colorectal cancer) that have failed…
- Trial name
- NCT04911907
- Testing
- utidelone injection
- Where
- 3 sites in China
- Volunteers
- 126 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer, Neoadjuvant Therapy
Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer
The purpose of this clinical trial is to evaluate the efficacy and safety of Utidelone based regimen as neoadjuvant treatment With High-risk Early-stage or Locally Advanced Breast Cancer.
- Trial name
- NCT05983094
- Testing
- Utidelone, Carboplatin, Epirubicin
- Where
- China
- Volunteers
- 181 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Ovarian Cancer, Fallopian Tube Cancer
Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This is an open, multicenter, phase II clinical study enrolling patients with platinum-resistant advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer to evaluate the safety and efficacy of Utidelone Capsules.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT07044349
- Testing
- Utidelone capsule 75mg/m2/d QD, Utidelone capsule 40mg/m2/d BID, Utidelone capsule 50mg/m2/d BID
- Volunteers
- 72 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Soft Tissue Sarcoma (STS), Utidelone
Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma
This trial is an open, multicenter, phase II clinical trial evaluating the efficacy and safety of uterostatin capsules (UTD2) combined with doxorubicin and tislelizumab in the treatment of advanced soft tissue sarcoma.
- Conditions
- Soft Tissue Sarcoma (STS), Utidelone, Doxorubicin
- Trial name
- NCT07842276
- Testing
- UTD2 + tislelizumab + doxorubicin
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
This trial is an open, multicenter, phase II clinical trial to evaluate the efficacy and safety of Utidelone capsules in patients with advanced solid tumors.
- Conditions
- Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer, Bile Duct Cancer
- Trial name
- NCT06730581
- Testing
- Utidelone Capsule 60mg/m2/d, Utidelone capsule 75mg/m2, Utidelone Capsule
- Volunteers
- 100 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer Recurrent
Utidelone Capsule Plus Capecitabine (CAP) for Metastatic Breast Cancer
This study aims to investigate the efficacy and safety of utidelone capsule plus Capecitabine in the treatment of advanced breast cancer , and thus provides a new systemic treatment strategy for those patients.
- Trial name
- NCT06458413
- Testing
- Utidelone Capsule Plus Capecitabine
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Min Yan, MD
TNBC - Triple-Negative Breast Cancer
The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study
This is a multicenter, open-label, single-arm clinical study designed to evaluate the safety and efficacy of Utidelone plus Tirelizumab and Bevacizumab for advanced or metastatic triple-negative breast cancer (TNBC).
- Trial name
- UTILIZABLE (NCT06125080)
- Testing
- Utidelone, Tirelizumab, Bevacizumab
- Where
- China
- Volunteers
- 78 people
- Sponsor
- Huihua Xiong
Advanced Solid Tumor
Phase I-II Clinical Trial of Utidelone Capsule in Patients With Advanced Solid Tumors
This study has three parts. Part 1 is a dose-escalation trial, Part 2 is a pharmacokinetic comparison and food effect study, and Part 3 is extended trial of combination of utidelone capsule and capecitabine.
- Trial name
- NCT05700084
- Testing
- Utidelone Capsule (Part 1), Drug A Utidelone Capsule (Part 2: Group A-B), Drug A Utidelone Capsule (Part 2: Group B-A)
- Where
- 10 sites in China
- Volunteers
- 84 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Breast Cancer
Utidelone Plus Bevacizumab for Advanced Breast Cancer With Brain Metastases
This study aims to investigate the efficacy and safety of utidelone in combination with bevacizumab in the treatment of advanced breast cancer with brain metastases, and thus provides a new systemic treatment strategy for those…
- Trial name
- NCT05357417
- Testing
- utidelone, Bevacizumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Henan Cancer Hospital
Non-small Cell Lung Cancer Patients with Brain Metastases
Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases
This study is a prospective, multicenter, two-stage phase II clinical trial evaluating the efficacy and safety of Utidelone combined with Bevacizumab in patients with non-small cell lung cancer with brain metastases.
- Trial name
- NCT06683703
- Testing
- Utidelone combined with Bevacizumab, Utidelone
- Volunteers
- 118 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
Advanced Non-small Cell Lung Cancer
Clinical Study of Utidelone Injection in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）
To assess the effectiveness and safety of utidelone injection in patients with advanced or metastatic NSCLC as a phase II trial
- Trial name
- NCT03693547
- Testing
- utidelone injection
- Where
- 4 sites in China
- Volunteers
- 26 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.
HER2-negative Breast Cancer Patients With Brain Metastases
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
This study is a multicenter, two-stage clinical trial to evaluate the efficacy and safety of utidelone in combination with capecitabine in patients with HER2-negative breast cancer with brain metastases.
- Trial name
- NCT06764940
- Testing
- Utidelone, Utidelone in combination with capecitabine
- Where
- 12 sites in United States
- Volunteers
- 120 people
- Sponsor
- Biostar Pharma, Inc.
HER-2 Negative Breast Cancer
Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
This study is a prospective, single-arm, open-label phase II study to evaluate the efficacy and safety of the combination of Utidelone and bevacizumab regimen in patients with ≥ 2 lines of HER-2 negative advanced breast cancer.
- Trial name
- NCT05398861
- Testing
- utidelone injection, Bevacizumab
- Where
- China
- Volunteers
- 79 people
- Sponsor
- Henan Cancer Hospital
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this clinical trial is to compare Utidelone with Docetaxel in patients with locally advanced or metastatic non-small cell lung cancer previously failed platinum-containing chemotherapy regimens.
- Trial name
- NCT05673590
- Testing
- Utidelone Injection, Docetaxel Injection
- Where
- China
- Volunteers
- 612 people
- Sponsor
- Beijing Biostar Pharmaceuticals Co., Ltd.